MetaCap

Kailera Therapeutics (KLRA) vs Sarepta Therapeutics (SRPT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kailera Therapeutics is the larger company by market cap ($1.43 billion vs $1.43 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KLRA-57.62%SRPT-38.14%
+11%-27%-65%
Apr 17, 20261 yearNov 20, 2026
KLRA-57.62%SRPT-38.14%
+8%-28%-63%
Apr 13, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KLRA versus SRPT key metrics
MetricKLRASRPT
Share price$11.02$13.33
Market cap$1.43B$1.43B
1-day change-4.84%-5.93%
YTD return—-38.06%
1-year return—-24.65%
5-year return—-83.26%
P/E ratio (TTM)—666.50
Forward P/E—8.87
EPS (TTM)$-4.16$0.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.20B
Revenue growth (YoY)—+15.58%
Net income (latest FY)—$-713.41M
Gross margin—98.84%
Operating margin—-31.83%
Net margin—-32.45%
52-week high$28.23$24.68
52-week low$9.76$13.25
Distance from 52-week high-60.96%-45.99%
Analyst consensusstrong_buyhold
Avg. price target upside+290.20%+63.32%
Average volume1.08M2.70M
Shares outstanding129.85M107.24M
Employees145835
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Kailera Therapeutics

KLRA stock →

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees

About Sarepta Therapeutics

SRPT stock →

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.

Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees

KLRA vs SRPT FAQ

Which is bigger, Kailera Therapeutics or Sarepta Therapeutics?

Kailera Therapeutics (KLRA) is larger, with a market capitalization of $1.43B compared with $1.43B for Sarepta Therapeutics (SRPT).

Are Kailera Therapeutics and Sarepta Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons